Page last updated: 2024-11-07

bisdequalinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

bisdequalinium: Salvizol is N(1),N(1')-decamethylene-N(4),N(4')-decamethylene-bis-4-aminoquinaldinium-diacetate 0.5% in propylene glycol, pH 6.6; RN given refers to parent cpd; structure; BIS-DEQUALINIUM & SALVISOL were ENs to DEQUALINIUM 1984-93 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159796
CHEMBL ID2110751
CHEBI ID135886
MeSH IDM0065197

Synonyms (18)

Synonym
n(sup 1),n(sup 1)'-dekamethylen-n(sup 4),n(sup 4)'-dekamethylen-bis-4-amino-chinaldinium
bisdequalinium
r 199
n,n'-decamethylene-n(4),n(4')-decamthylenebis(4-aminoquinaldinium chloride)
quinaldinium, 1,1'-decamethylene-4,4'-(decamethylenediimino)di-, dibromide
5,34:16,21-diethenodibenzo(b,r)(1,5,16,20)tetraazacyclotriaconti-5,16-diium, 6,7,8,9,10,11,12,13,14,15,22,23,24,25,26,27,28,29,30,31,32,33-docosahydro-36,38-dimethyl-, dibromide
CHEBI:135886
16776-40-2
n848p5o593 ,
unii-n848p5o593
bisdequalinium cation
bisdequalinium ion
5,34:18,23-diethenodibenzo(b,r)(1,5,16,20)tetraazacyclotriacontine-23,34-diium, 6,7,8,9,10,11,12,13,14,15,16,17,24,25,26,27,28,29,30,31,32,33-docosahydro-35,37-dimethyl-
bisdequalinium [who-dd]
6,7,8,9,10,11,12,13,14,15,16,17,24,25,26,27,28,29,30,31,32,33-docosahydro-35,37-dimethyl-5,34:18,23-diethenodibenzo(b,r)(1,5,16,20)tetraazacyclotriacontine-23,24-diium
CHEMBL2110751
39,42-dimethyl-20,31-diaza-1,12-diazoniapentacyclo[30.6.2.212,19.013,18.033,38]dotetraconta-1(39),12(42),13,15,17,19(41),32(40),33,35,37-decaene
Q27284693
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (88.46)18.7374
1990's2 (7.69)18.2507
2000's0 (0.00)29.6817
2010's1 (3.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]